POLE encodes the catalytic subunit of DNA polymerase epsilon, the enzyme that replicates the leading strand of DNA during cell division and participates in DNA repair. It contains a proofreading domain that corrects replication errors, keeping the accumulation of mutations in check. Germline mutations in POLE cause polyposis and predispose to colorectal cancer, and are also linked to a rare syndrome of facial dysmorphism, immunodeficiency, livedo, and short stature. Somatic mutations, particularly in the proofreading domain, occur in colorectal and endometrial cancers, where they drive an ultra-mutated tumor phenotype and are associated with better responses to immune checkpoint inhibitors.

POLE mutations cause polyposis, colorectal cancer predisposition, and, through proofreading-domain changes, an ultra-mutated tumor phenotype; this synonymous variant alters no amino acid and shows no splice impact, so it does not engage any known POLE disease mechanism. Its VUS classification reflects extreme rarity in population databases but no functional, segregation, or case-level evidence linking it to disease, leaving its clinical relevance unresolved.